title: Nonserious infections: should there be cause for serious concerns?
abstract: Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.
authors.affiliation: Baylor Research Institute, Dallas, TX 75229, USA. daokathryn@yahoo.com
authors.forename: Kathryn H
authors.initials: KH
authors.lastname: Dao
authors.forename: Morley
authors.initials: M
authors.lastname: Herbert
authors.forename: Nadia
authors.initials: N
authors.lastname: Habal
authors.forename: John J
authors.initials: JJ
authors.lastname: Cush
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects; D000069285:Infliximab; D009894:Opportunistic Infections / Q000453:epidemiology*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept